Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 3/20 | 0.58 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.54 |
| ▸ | ADK | P55263 | 2/20 | 0.48 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.43 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733384 | 1.00 | PRMT5 (0.58) | PRMT5WDR77ADORA3ADORA2AADORA1 | |
| SCHEMBL14089358 | 0.91 | ADORA3 (0.57) | PRMT5WDR77ADORA3ADORA2AADORA1 | |
| SCHEMBL13598817 | 0.91 | ADORA3 (0.57) | PRMT5WDR77ADORA3ADORA2AADORA1 | |
| SCHEMBL4430766 | 0.91 | ADORA3 (0.57) | PRMT5WDR77ADORA3ADORA2AADORA1 | |
| SCHEMBL13598664 | 0.91 | ADORA3 (0.57) | PRMT5WDR77ADORA3ADORA2AADORA1 | |
| SCHEMBL4432672 | 0.89 | ADORA3 (0.55) | PRMT5WDR77ADORA3ADORA2AADORA1 | |
| SCHEMBL13598665 | 0.89 | ADORA3 (0.55) | PRMT5WDR77ADORA3ADORA2AADORA1 | |
| SCHEMBL14089611 | 0.89 | ADORA3 (0.55) | PRMT5WDR77ADORA3ADORA2AADORA1 | |
| SCHEMBL733121 | 0.88 | ADORA3 (0.66) | PRMT5WDR77ADORA3ADORA2AADORA1 | |
| SCHEMBL14782094 | 0.88 | ADORA3 (0.66) | PRMT5WDR77ADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309412-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | IONIS PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| EP-2618665-A1 | HCV NS3 PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012040040-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309412-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | NSUN2, NSUN3, POLRMT | PRMT5 436/4885WDR77 1478/4885ADORA3 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.